Loading...
Market
Will PacBio's SPRQ Chemistry Capture 50% Market Share in Genome Sequencing by End of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market analysis reports from industry analysts like Gartner or IDC
Story
PacBio Unveils SPRQ Chemistry for Revio, Cutting Genome Sequencing Costs to $500
Oct 29, 2024, 04:41 PM
Pacific Biosciences (PacBio) has announced a significant advancement in its sequencing technology with the introduction of SPRQ chemistry for the Revio Sequencing Systems. This new long-read sequencing chemistry is expected to reduce the cost of sequencing a human genome to less than $500, which represents a 50% reduction in sequencing costs. The improvements are anticipated to increase the system's output and efficiency, marking a major milestone for the company and the genomics industry. This development is seen as an 'inflection point' for PacBio, potentially transforming the economics of genome sequencing. The announcement was made at ASHG24, and its impact on Kinnex will be discussed separately.
View original story
Similar markets
Below 5% • 25%
5%-10% • 25%
10%-15% • 25%
Above 15% • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Illumina • 25%
Thermo Fisher Scientific • 25%
Bio-Rad Laboratories • 25%
Other • 25%
A cancer diagnostics company • 25%
A gene sequencing company • 25%
A biotech company unrelated to cancer diagnostics • 25%
No major acquisition • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
